Foghorn therapeutics announces clinical data from phase 1 study of fhd-286 in metastatic uveal melanoma to be presented at esmo congress

Cambridge, mass., oct. 13, 2023 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the dose escalation and expansion study of fhd-286 in metastatic uveal melanoma (mum) will be presented at the esmo congress 2023, to be held october 20–24 in madrid, spain.
FHTX Ratings Summary
FHTX Quant Ranking